Heidi Besen / Shutterstock.com
The COVID-19 pandemic has seen the fundamental principles of the IP system, normally a touchstone of advanced economies, called into question. Governments and manufacturers alike are under pressure to assure the public that IP will not be a barrier to accessing the tools needed to fight the disease.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
COVID-19, compulsory licensing, patent, drugs, pharmaceuticals, Big Pharma, pandemic, Gilead, remdesivir, WHO, IFPMA, Heidi Chow, Global Justice Now